These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28315913)

  • 1. Does dual-time-point
    Wu B; Zhao Y; Zhang Y; Tan H; Shi H
    Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of
    Wu B; Zhang Y; Tan H; Shi H
    Abdom Radiol (NY); 2019 Jul; 44(7):2430-2435. PubMed ID: 30944961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases.
    Mao W; Zhou J; Qiu L; Yin H; Tan H; Shi H
    Abdom Radiol (NY); 2020 Apr; 45(4):1075-1081. PubMed ID: 31927618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
    Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
    Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
    Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited diagnostic value of Dual-Time-Point (18)F-FDG PET/CT imaging for classifying solitary pulmonary nodules in granuloma-endemic regions both at visual and quantitative analyses.
    Chen S; Li X; Chen M; Yin Y; Li N; Li Y
    Eur J Radiol; 2016 Oct; 85(10):1744-1749. PubMed ID: 27666611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of early dynamic and delayed post-diuretic
    Sharma A; Mete UK; Sood A; Kakkar N; Gorla AK; Mittal BR
    Br J Radiol; 2017 Apr; 90(1072):20160787. PubMed ID: 28256904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Na SJ; Oh JK; Hyun SH; Lee JW; Hong IK; Song BI; Kim TS; Eo JS; Lee SW; Yoo IR; Chung YA; Yun M
    J Nucl Med; 2017 May; 58(5):730-736. PubMed ID: 27789714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
    Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
    Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL; Chen S; Yeung DW; Cheng TK
    J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
    Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
    J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
    Karan B; Pourbagher A; Torun N
    J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
    Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
    J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.